3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Lymphoma
3
Stomatitis
2
Small Cell Lung Carcinoma
2
Neoplasms
2
Mucositis
2
Mouth Neoplasms
2
Lung Neoplasms
2
Head and Neck Neoplasms
2
Carcinoma, Small Cell
2
Brain Neoplasms
2
Spinal Cord Neoplasms
1
Neuroendocrine Tumors
1
Neoplasm Metastasis
1
Colorectal Neoplasms
1
Cholangiocarcinoma
1
Central Nervous System Neoplasms
1
Carcinoma, Squamous Cell
1
Carcinoma, Ovarian Epithelial
1
Carcinoma, Non-Small-Cell Lung
1
Interventions
Gemcitabine
28
pembrolizumab
24
Cisplatin
24
Fluorouracil
11
Leucovorin
10
Oxaliplatin
8
Nivolumab
7
Capecitabine
6
Irinotecan
5
Drug Therapy
5
pemigatinib
4
futibatinib
4
Paclitaxel
4
Carboplatin
4
ivosidenib
3
durvalumab
3
derazantinib
3
Folfox protocol
3
Bevacizumab
3
zanidatamab
2
spartalizumab
2
olutasidenib
2
lenvatinib
2
infigratinib
2
fludarabine
2
budigalimab
2
Trastuzumab
2
Ipilimumab
2
Injections
2
Docetaxel
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
INDUSTRY
×
Cholangiocarcinoma
×
RRx-001
×
Clear all
NCT02452970
2024-04-24
EPIC
EpicentRx, Inc.
Phase 2
Terminated
4 enrolled
6 charts